Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALCAINE vs OMEPRAZOLE AND SODIUM BICARBONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Sodium bicarbonate is an antacid that neutralizes gastric acid.
Ophthalmic anesthesia for procedures such as cataract extraction, tonometry, gonioscopy, and suture removal
Duodenal ulcer,Gastric ulcer,Gastroesophageal reflux disease (GERD),Erosive esophagitis,Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome),Helicobacter pylori eradication (in combination with antibiotics),Prevention of upper gastrointestinal bleeding in critically ill patients (off-label),Treatment of dyspepsia (off-label)
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
Omeprazole 20 mg plus sodium bicarbonate 1100 mg orally once daily before a meal; for gastroesophageal reflux disease, dose may be increased to 40 mg orally once daily for 4-8 weeks.
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Terminal elimination half-life of omeprazole is approximately 0.5-1 hour. However, the pharmacodynamic effect (gastric acid suppression) lasts longer due to accumulation in parietal cells. Half-life does not correlate with duration of acid suppression.
Hydrolyzed by plasma esterases.
Omeprazole is extensively metabolized in the liver by cytochrome P450 (CYP) enzymes, primarily CYP2C19 and CYP3A4, to inactive metabolites. Sodium bicarbonate is not metabolized; it dissociates into sodium and bicarbonate ions.
Renal excretion of parent drug and metabolites: <5% unchanged.
Omeprazole is primarily metabolized by CYP2C19 and CYP3A4; metabolites are excreted renally (~77% as metabolites) and fecally (~20% as metabolites). Urinary excretion of unchanged omeprazole is negligible (<1%). Sodium bicarbonate is excreted renally as bicarbonate and carbon dioxide.
Minimal; <5% bound to plasma proteins.
Omeprazole is 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Not clinically meaningful due to rapid hydrolysis; Vd estimated <0.5 L/kg (low, consistent with high water solubility and rapid clearance).
Apparent volume of distribution is approximately 0.3-0.5 L/kg, suggesting distribution into total body water. The active form accumulates in parietal cell canaliculi.
Ophthalmic topical: negligible systemic absorption (minimal bioavailability); not applicable systemically.
Oral bioavailability is approximately 30-40% after a single dose, increasing to 60-70% with repeated administration due to decreased first-pass metabolism. Bioavailability is not affected by food but is enhanced by the sodium bicarbonate component, which protects omeprazole from acid degradation.
No dose adjustment required; negligible systemic absorption.
No dosage adjustment required for mild to moderate renal impairment; for severe renal impairment (GFR <30 m L/min), use with caution and monitor for sodium overload.
No dose adjustment required; negligible systemic absorption.
For mild hepatic impairment (Child-Pugh class A), no adjustment; for moderate to severe impairment (Child-Pugh class B or C), maximum dose is 20 mg omeprazole once daily due to reduced metabolism.
1 drop of 0.5% solution topically to the eye, repeated as needed; maximum 1 drop per dose in infants and young children to avoid systemic effects.
Not established for omeprazole/sodium bicarbonate combination; for omeprazole alone, weight-based dosing: 10-15 mg once daily for weight 10-20 kg, 20 mg once daily for weight >20 kg.
No specific adjustment; use lowest effective dose due to potential increased corneal sensitivity and delayed healing.
No specific dose adjustment; use lowest effective dose, monitor for electrolyte imbalance (sodium) and increased risk of Clostridium difficile infection.
Not for injection or prolonged use; corneal toxicity with repeated or prolonged use.
No FDA black box warning.
Prolonged use may cause corneal epithelial damage and delay wound healing. Avoid contamination of the dropper tip.
Gastric malignancy: Short-term treatment does not preclude presence of gastric malignancy.,Clostridioides difficile infection: May increase risk.,Bone fracture: Long-term use may increase risk of osteoporosis-related fractures of the hip, wrist, or spine.,Hypomagnesemia: May cause low serum magnesium with prolonged use.,Cyanocobalamin (Vitamin B12) deficiency: Prolonged acid suppression may impair absorption.,Acute interstitial nephritis: Has been observed.,Cutaneous lupus erythematosus: May increase risk.,Interaction with methotrexate: May increase methotrexate toxicity.,Sodium content: Contains sodium bicarbonate; caution in patients on sodium-restricted diet.,Metabolic alkalosis: High doses of bicarbonate may cause metabolic alkalosis.
Hypersensitivity to any component of the formulation.
Hypersensitivity to omeprazole or sodium bicarbonate,Hypersensitivity to other proton pump inhibitors,Concurrent use of rilpivirine,Severe hypokalemia or metabolic alkalosis (due to bicarbonate component)
None known.
Avoid taking with food or within 30 minutes of eating. High-fat meals may delay absorption. No specific food restrictions, but alcohol and spicy foods may exacerbate symptoms.
Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects at doses up to 0.5 mg/kg (SC). Potential fetal risk unlikely to exceed background risk. No known trimester-specific risks.
First trimester: No increased risk of major congenital malformations based on large cohort studies. Second and third trimesters: Limited data, but no evidence of fetal harm. Omeprazole is FDA Pregnancy Category C; sodium bicarbonate is not associated with teratogenicity.
Proparacaine is excreted into breast milk in unknown amounts, but due to minimal systemic absorption, the expected dose to infant is negligible. Manufacturer advises caution. No M/P ratio available.
Omeprazole is excreted into breast milk with an M/P ratio of approximately 0.1-0.2. Sodium bicarbonate is also excreted. At therapeutic doses, amounts are unlikely to affect the infant. Manufacturer advises caution, but use is generally considered compatible with breastfeeding.
No dosing adjustment required for topical ophthalmic use due to negligible systemic absorption and lack of pharmacokinetic alterations in pregnancy.
Pregnancy does not significantly alter omeprazole pharmacokinetics. No dose adjustment required, but use lowest effective dose due to limited safety data. Sodium bicarbonate dose may need adjustment if renal impairment or preeclampsia is present.
ALCAINE (proparacaine) is a topical ophthalmic anesthetic. Onset within 20 seconds, duration ~15 minutes. Do not dispense for home use due to risk of corneal toxicity with prolonged use. Use a sterile, single-dose vial to prevent contamination. Monitor for stinging or burning on instillation. Avoid in patients with sulfite allergy (contains sodium bisulfite).
Administer on an empty stomach 1 hour before a meal for maximal acid suppression. The sodium bicarbonate component provides rapid antacid effect and may cause belching or gastric distension. Avoid in patients with Bartter's syndrome, hypokalemia, or metabolic alkalosis. Monitor magnesium levels with prolonged use; hypomagnesemia can occur with PPIs. For patients unable to swallow capsules, the contents can be mixed with applesauce.
Temporary stinging or burning may occur upon application.,Do not touch the dropper tip to any surface to avoid contamination.,Do not use for more than instructed; prolonged use can damage the cornea.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Notify your doctor if you have a sulfite allergy.
Take this medication 1 hour before a meal, usually once daily.,Swallow the capsule whole; do not crush or chew. If you have trouble swallowing, open the capsule and mix the granules with a tablespoon of applesauce, then swallow immediately.,Do not take with other antacids unless directed by your doctor.,Inform your doctor if you experience severe diarrhea, muscle cramps, irregular heartbeat, or signs of low magnesium (seizures, dizziness, abnormal heart rhythm).,Long-term use may increase risk of bone fractures, vitamin B12 deficiency, and kidney problems.
No interactions on record
"Niclosamide may inhibit the cytochrome P450 enzyme CYP2C19, which is the primary hepatic enzyme responsible for the metabolism of omeprazole. This inhibition can lead to decreased clearance and elevated plasma concentrations of omeprazole, potentially increasing its therapeutic and adverse effects. Clinically, this could result in enhanced acid suppression and an increased risk of omeprazole-related side effects such as headache, diarrhea, or vitamin B12 deficiency with prolonged use."
"Cyclosporine, a potent immunosuppressant and P-glycoprotein inhibitor, can significantly increase the systemic exposure of omeprazole by inhibiting its efflux transport and potentially its metabolism via CYP3A4 and CYP2C19. This interaction may lead to elevated omeprazole serum concentrations, increasing the risk of adverse effects such as headache, diarrhea, and vitamin B12 deficiency with long-term use. Clinicians should be vigilant for signs of omeprazole toxicity when coadministered with cyclosporine."
"Omeprazole, a proton pump inhibitor (PPI), is primarily metabolized by cytochrome P450 (CYP)2C19 and, to a lesser extent, CYP3A4. Stiripentol, an antiepileptic drug, is a potent inhibitor of CYP2C19 and CYP3A4. Coadministration may lead to a significant increase in omeprazole exposure (AUC up to 5-fold), potentially increasing the risk of adverse effects such as hypomagnesemia, Clostridioides difficile infection, or bone fracture. Conversely, stiripentol levels are not expected to be significantly affected, as omeprazole does not inhibit its metabolism."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALCAINE vs OMEPRAZOLE AND SODIUM BICARBONATE, answered by our medical review team.
ALCAINE is a Local Anesthetic that works by Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.. OMEPRAZOLE AND SODIUM BICARBONATE is a Alkalinizing Agent that works by Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Sodium bicarbonate is an antacid that neutralizes gastric acid.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALCAINE and OMEPRAZOLE AND SODIUM BICARBONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALCAINE is: 1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.. The standard adult dose of OMEPRAZOLE AND SODIUM BICARBONATE is: Omeprazole 20 mg plus sodium bicarbonate 1100 mg orally once daily before a meal; for gastroesophageal reflux disease, dose may be increased to 40 mg orally once daily for 4-8 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALCAINE and OMEPRAZOLE AND SODIUM BICARBONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALCAINE is classified as Category C. Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant wom. OMEPRAZOLE AND SODIUM BICARBONATE is classified as Category A/B. First trimester: No increased risk of major congenital malformations based on large cohort studies. Second and third trimesters: Limited data, but no evidence of fetal harm. Omepra. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.